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Patients on maintenance peritoneal dialysis (PD) are frequently
complicated with volume overload. In this study, we sought to
evaluate troponin T testing alone or in combination with
echocardiographic measures in predicting cardiovascular
congestion in PD patients. This was a prospective study of 222
chronic PD patients with echocardiography and measurement
of serum troponin T carried out at baseline. Patients were
followed for 3 years or until death. The end point was first
episode of cardiovascular congestion. Troponin T emerged as
an independent predictor of cardiovascular congestion
(hazard ratio, 2.98, 95% confidence intervals (CI), 1.19–7.42) in
a multivariable Cox regression model, including also left
ventricular mass index (LVMi) and ejection fraction (EF).
Patients with troponin T4median (0.06 lg/l) and EFp50%
and patients with troponin T4median but EF450% had a
3.10-fold (95% CI, 1.71–5.63) and 1.88-fold (95% CI, 1.05–3.38)
adjusted risk of cardiovascular congestion, respectively, than
those with troponin Tpmedian and EF450%. Patients with
troponin T4median and LVMiXmedian (96.23 g/m2.7) had a
2.68-fold (95% CI, 1.39–5.19) adjusted risk of cardiovascular
congestion than those with troponin Tpmedian and LVMi
omedian. In conclusion, troponin T predicts cardiovascular
congestion in chronic PD patients without acute myocardial
ischemia and provides incremental prognostic value for
cardiovascular congestion when used in combination with
LVM and EF. This easily available parameter adds significant
value to echocardiography in identifying PD patients at risk of
cardiovascular congestion.
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End-stage renal disease patients are at an accelerated risk of
developing cardiovascular complications. According to a
previous study by Harnett et al.,1 up to a-third of the end-
stage renal disease patients on dialysis developed heart failure
on initiation of dialysis, of which 56% had further
recurrences. Even for patients with no heart failure at
baseline, around 25% was complicated with heart failure at
a rate of 7% per year. More importantly, the presence of heart
failure at initiation of dialysis and its recurrence were both
significant predictors of mortality in patients on maintenance
dialysis. Thus, the ability to early identify patients at risk of
this complication may optimize therapeutic interventions,
reduce this complication, and improve the adverse outcomes
of dialysis patients.
Echocardiography provides an assessment of left ventri-
cular hypertrophy and dysfunction, and is an important tool
in evaluating dialysis patients with heart failure and volume
overload. Indeed, the presence of pre-existing systolic
dysfunction predisposed dialysis patients to a greater risk of
heart failure.1 Experimental and clinical studies showed that
necrosis- or apoptosis-mediated myocyte loss during ven-
tricular remodeling may play a contributory role to the
progression of left ventricular dysfunction.2–6 However, the
study of this process requires myocardial biopsy, which is
invasive and difficult to perform in humans. Measurement of
serum biomarkers that reflect myocyte injury is relatively
simple, noninvasive and may allow better characterization of
the nature of cardiac disease.
Among these different biomarkers, cardiac troponin T is a
highly sensitive and specific marker of myocardial necrosis.
Troponin T measurement is useful in diagnosing acute
coronary syndrome7 and is a powerful, independent risk
marker in acute coronary syndrome.8 Troponin T is also
increased in patients with heart failure and nonischemic
disorders,9–15 and predicts prognosis in the nonrenal failure
population with heart failure, suggesting that troponin T may
be a marker of subclinical myocyte injury/necrosis.
Circulating troponin T is frequently elevated in chronic
kidney disease and dialysis patients without evidence
of acute myocardial ischemia.16,17 Its elevation has been
partly attributed to accumulation of troponin T fragments
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secondary to impaired renal clearance.18 In patients with
acute coronary syndrome, troponin T retains its prognostic
significance even when renal function is impaired.19 In
addition, elevated troponin T shows important association
with left ventricular hypertrophy and dysfunction,20 and is
predictive of mortality and cardiovascular death in end-stage
renal disease patients on maintenance dialysis.21–25 Given that
troponin T represents a highly sensitive and specific marker
of myocyte injury/necrosis and volume overload is a frequent
complication in chronic peritoneal dialysis patients, we
hypothesized that troponin T alone or in combination with
left ventricular mass and ejection fraction (EF) may serve as
important parameters that predict cardiovascular congestion
in these patients.
RESULTS
The baseline clinical, demographic, biochemical and dialysis
characteristics are shown in Table 1. Eighty-five patients
(38.3%) developed cardiovascular congestion during follow-
up, of which 49 patients had 1 episode, 19 patients had 2
episodes and 17 patients had 3 or more episodes of
cardiovascular congestion. Baseline median (interquartile
range) troponin T was 0.1 (0.03, 0.2) mg/l for patients who
subsequently developed cardiovascular congestion versus 0.03
(0.01, 0.09) mg/l for those who did not (Po0.001). Table 2
shows the baseline echocardiographic parameters. Troponin
T showed positive correlations with left ventricular mass
index (LVMi) by height2.7 (Spearman r¼ 0.44, Po0.001), left
ventricular volume in end-diastole index by body surface area
(r¼ 0.46, Po0.001), left ventricular posterior wall thickness
in end-diastole (r¼ 0.33, Po0.001), and interventricular
septal wall thickness in end-diastole (r¼ 0.30, Po0.001) and
negative correlations with left ventricular EF (r¼0.32,
Po0.001) and fractional shortening (r¼0.33, Po0.001).
Predictors of cardiovascular congestion
The univariate Cox regression analysis for cardiovascular
congestion is shown in Table 3. Table 4 displays the
multivariable Cox regression models for cardiovascular
congestion. Troponin T remained an independent predictor
of cardiovascular congestion when adjusting for LVMi and EF
in addition to other covariates in the base model (Model 3).
Kaplan–Meier estimates of cardiovascular congestion-event
free probability for all patients according to quartiles of
troponin T are shown in Figure 1.
Figure 2a shows the Kaplan–Meier estimates of cardiovas-
cular congestion-event free probability for patients stratifying
into four groups on the basis of troponin Tpmedian (0.06mg/
l) and 4median and LVMi omedian (96.23 g/m2.7) and
Xmedian. The prevalence as well as frequency of recurrence
of cardiovascular congestion during the 3-year follow-up were
the highest among patients with LVMiXmedian and troponin
T4median (Po0.001; Figure 2b). The multivariable Cox
regression analysis with patients stratified into four groups on
the basis of troponin T4median or pmedian and LVMiX
median and omedian is shown in Table 5.
Figure 3a shows the Kaplan–Meier estimates of cardiovas-
cular congestion-event free probability for patients stratifying
into four groups on the basis of troponin Tpmedian
and 4median and EFp50% and 450%. The prevalence
as well as frequency of recurrence of cardiovascular
congestion during follow-up were the highest among patients
with troponin T4median and EFp50% (Po0.001;
Figure 3b). Table 6 shows the multivariable Cox regression
analysis with patients stratified into four groups on the basis
of troponin T4median or pmedian and EF450%
and p50%.
DISCUSSION
The principal finding of this study was that cardiac troponin
T was an independent predictor of cardiovascular congestion
in chronic peritoneal dialysis patients. When considered as
separate risk factors, troponin T appeared prognostically
more important than LVMi or left ventricular EF in
determining the risk of cardiovascular congestion. In
addition, troponin T provides incremental prognostic value
for cardiovascular congestion when used in combination with
LVMi and left ventricular EF.
Prognostic value of troponin T for cardiovascular congestion
Studies in the general population showed that 25–50% of
patients with heart failure had increased troponin T26,27 and
that increased troponin T correlated with the severity of heart
failure,10–12 and was associated with left ventricular hyper-
trophy and systolic dysfunction.14 Increased troponin T was
predictive of a worse prognosis in both acute and chronic
heart failure.9,26–28 In patients with nonischemic dilated
cardiomyopathy, persistently elevated troponin T was asso-
ciated with further deterioration of heart failure and a worse
outcome,29,30 suggesting that troponin T is a marker of
subclinical myocardial injury. In end-stage renal disease, the
association between troponin T with left ventricular mass and
function20,31 is further confirmed in this study of peritoneal
dialysis patients. Troponin T has also been shown to be
associated with mortality and cardiovascular events23,31 and
with coronary atherosclerosis and cardiomyopathy.23 The
current finding that troponin T retained important prog-
nostic value for cardiovascular congestion independent of left
ventricular hypertrophy and EF and that troponin T elevation
was prognostically more important than left ventricular
hypertrophy and systolic dysfunction in predicting cardio-
vascular congestion when considered as separate risk factors
suggests troponin T elevation in chronic peritoneal dialysis
patients may signify something more than cardiac hyper-
trophy and dysfunction or coronary athersclerosis. As none
of the study patients had acute myocardial infarction at the
time of study or within recent 1 month before study entry, it
is unlikely that troponin T elevation reflects an acute event.
We speculate that troponin T elevation may reflect a more
gradual process such as subclinical myocardial necrosis or
fibrosis and represent a more global marker of diseased
myocardium and left ventricular dysfunction, thus explaining
Kidney International (2006) 70, 444–452 445
AY-M Wang et al.: Troponin T predicts cardiovascular congestion in dialysis o r i g i n a l a r t i c l e
its strong and independent association with cardiovascular
congestion. Our data provide important evidence that
troponin T appears to be a more precise and accurate
measure than echocardiographic parameters such as LVMi
and EF in predicting cardiovascular congestion in peritoneal
dialysis.
Indeed, being a highly sensitive and specific marker of
myocardial necrosis, troponin T has been shown to confirm
acute myocardial ischemia in the general population32 and
predicts an increased risk of death or adverse cardiac events
following an episode of acute coronary syndrome.8 Even
though the degree of troponin T elevation may be
confounded by renal impairment,33 its prognostic value for
acute myocardial ischemia remains irrespective of the degree
of renal impairment.22 There is emerging evidence that
troponin T, which is frequently elevated in asymptomatic
dialysis patients,20,21 is a powerful predictor of mortality and
cardiovascular death.21–25 Recent meta-analysis indicated that
an elevated troponin T40.1 mg/l identifies a subgroup of
end-stage renal disease patients with poor survival and high
risk of cardiac death despite being asymptomatic.34 The exact
mechanism of this association has remained unclear although
study has indicated that patients with detectable circulating
troponin T showed histologic changes, including patchy
fibrosis and degenerative myocyte changes characteristics
of heart failure.35 This gave additional evidence that an
elevated troponin T in chronic peritoneal dialysis patients
without acute myocardial ischemia may be indicative of
subclinical myocardial necrosis or injury and warrants
further evaluation.
Table 1 | Baseline clinical, demographic, biochemical, and dialysis characteristics
All patients
(n=222)
With cardiovascular
congestion (n=85)
No cardiovascular
congestion (n=137) P-value
Clinical and demographic data
Male gender 111 (50%) 44 (51.8%) 67 (48.9%) 0.68
Age (years) 56712 56.7711.1 55.2711.7 0.33
Body mass index (kg/m2) 23.173.4 23.373.5 22.973.3 0.45
Positive history of smoking 82 (36.9%) 37 (43.5%) 45 (32.8%) 0.11
Diabetes mellitus 67 (30.2%) 35 (41.2%) 32 (23.4%) 0.005
Known clinical atherosclerotic vascular disease 52 (23.4%) 28 (32.9%) 24 (17.5%) 0.008
Renal diagnosis
Chronic glomerulonephritis 70 (31.5%) 23 (27.1%) 47 (34.3%) 0.08
Diabetic nephropathy 55 (24.8%) 29 (34.1%) 26 (19.0%) —
Hypertensive nephrosclerosis 29 (13.1%) 11 (12.9%) 18 (13.1%) —
Others 68 (30.6%) 22 (25.9%) 49 (33.6%) —
Duration of dialysis, months 26.5 (15, 51) 25 (13, 49) 30 (16, 56) 0.10
Systolic blood pressure (mm Hg) 147717 152717 143716 o0.001
Diastolic blood pressure (mm Hg) 82710 83711 8279 0.55
Medications use
Erythropoietin 90 (40.5%) 38 (44.7%) 52 (38%) 0.32
Angiotensin converting enzyme inhibitor 55 (24.8%) 23 (27.1%) 32 (23.4%) 0.54
Beta-blocker 116 (52.3%) 46 (54.1%) 70 (51.1%) 0.66
Calcium channel blocker 135 (60.8%) 50 (58.8%) 85 (62%) 0.63
HMG-CoA reductase inhibitors 31 (14%) 14 (16.5%) 17 (12.4%) 0.40
Total number of anti-hypertensives 1.5370.96 1.6770.98 1.4570.94 0.09
Biochemical data
Hemoglobin (g/dl) 9.1471.68 8.6271.60 9.4671.66 o0.001
Serum urea (mmol/l) 24714 26722 2376 0.17
Serum creatinine (mmol/l) 10277274 10287246 10267291 0.96
Serum albumin (g/l) 28.575.1 27.675.4 29.174.8 0.03
Calciumphosphorus product (mmol2/l2) 4.3071.33 4.3271.30 4.2971.35 0.88
Parathyroid hormone (pmol/l) 42 (19, 75) 37 (19, 67) 44 (18, 82) 0.60
C-reactive protein (mg/l) 2.78 (0.93, 9.03) 3.20 (1.29, 7.07) 2.25 (0.82, 10.01) 0.36
Troponin T (mg/l) 0.06 (0.01, 0.15) 0.1 (0.03, 0.2) 0.03 (0.01, 0.09) o0.001
Dialysis indices data
Total urea clearance 1.8170.43 1.7870.44 1.8370.43 0.48
Peritoneal dialysis urea clearance 1.5370.35 1.5170.34 1.5470.36 0.45
Total creatinine clearance, l/week per 1.73 m2 56.4721.4 54.7719.2 57.4722.7 0.37
Residual GFR, ml/min per 1.73 m2 0.55 (0, 1.86) 0.49 (0, 1.60) 0.63 (0, 2.01) 0.45
Daily urine volume(l) 0.3970.53 0.3770.50 0.4070.55 0.68
Net daily peritoneal dialysis ultrafiltration (l) 0.9570.97 0.8870.98 0.9970.96 0.42
Total net daily ultrafiltration (l) 1.3270.97 1.2470.98 1.3770.96 0.32
High transporter status by PET 35 (15.9%) 18 (21.4%) 17 (12.5%) 0.08
GFR, glomerular filtration rate; PET, peritoneal equilibration test.
Values are mean7s.d. or median (interquartile range).
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The causes of subclinical myocardial injury are not
entirely clear although a number of factors including
recurrent episodes of ischemia/infarction in patients with
coronary artery disease, ventricular remodeling, abnormal-
ities of the coronary microcirculation,10,36 and increased wall
strain37 have all been implicated to play a role in mediating
the degradation of cardiac myocytes. Myocyte death/necrosis
has been hypothesized to be important pathomechanisms for
heart failure and contributes to progressive myocardial
dysfunction and ventricular remodeling in the general
population.2–6 However, it is currently not known whether
similar pathologic process occurs in patients on dialysis. The
evaluation of myocyte apoptosis/necrosis requires myocardial
biopsy, which is invasive and not without risk. In contrast,
troponin T measurement is routinely available in most
hospital laboratories at a relatively low cost, is quick and
noninvasive. It has the additional advantage of not being con-
founded by the presence of inflammation, unlike C-reactive
protein.
Added value of troponin T to echocardiography for predict-
ing cardiovascular congestion in peritoneal dialysis
Heart failure and volume overload are frequent complica-
tions in chronic dialysis patients.1 Pulmonary congestion was
present in 80% of chronic peritoneal dialysis patients with
volume overload.38 Previous study by Zoccali et al. has
reported the importance of left ventricular hypertrophy and
systolic function as predictors of cardiovascular events in
asymptomatic dialysis patients independent of other tradi-
tional and novel risk factors such as C-reactive protein and
asymmetric dimethylarginine. Of note, patients with both left
ventricular hypertrophy and systolic dysfunction showed the
greatest risk of cardiovascular events.39 As shown in our
study, echocardiography provides an important evaluation
of myocardial status and function in patients with cardio-
vascular congestion. The presence of more severe left
ventricular hypertrophy and systolic dysfunction on echo-
cardiography indeed predicts a higher subsequent risk of
cardiovascular congestion. Of greater importance is the novel
finding that troponin T provides additional prognostic value
when used in combination with left ventricular hypertrophy
and EF for predicting cardiovascular congestion in chronic
Table 2 | Baseline echocardiographic parameters
All patients
(n=222)
With cardiovascular
congestion (n=85)
No cardiovascular
congestion (n=137) P-value
M-mode and 2-D
LV mass index by height2.7 (g/m2.7) 104740 117744 96736 o0.001
LV volume in end-diastole index by body surface area (ml/m2) 65.9720.3 73.6722.7 61.1717.1 o0.001
LVPWd (cm) 1.370.3 1.470.3 1.370.3 0.16
IVSd (cm) 1.570.4 1.570.4 1.570.4 0.15
LV ejection fraction (%) 52.578.3 50.379.9 53.976.8 0.001
LV fractional shortening (%) 33.378.6 31.779.5 34.277.8 0.04
Patients with LV EFr50% 73 (32.9%) 38 (44.7%) 35 (25.5%) 0.003
Left atrial diameter end-systole (cm) 4.170.7 4.470.7 4.070.7 o0.001
Mitral inflow velocities
E (cm/s) 79727 81726 77727 0.22
A (cm/s) 92725 93725 91724 0.51
DTa (ms) 250710 23079 260711 0.12
DTr140 ms 20 (9.3%) 9 (11%) 11 (8.3%) 0.51
DT4140 ms 195 (90.7%) 73 (89%) 122 (91.7%)
E/Ab 0.970.5 1.070.6 0.970.4 0.26
LV, left ventricular; LVPWd, left ventricular posterior wall thickness in end-diastole; IVSd, interventricular septal wall thickness in end-diastole; EF, ejection fraction; E, early
diastolic transmitral flow velocity; A, late diastolic transmitral flow velocity; DT, deceleration time; E/A, ratio of early to late transmitral flow velocity.
Values are mean7s.d.
aDeceleration time could be assessed in 215 patients (97%).
bE/A ratio could be calculated in 212 patients (95%).
Table 3 | Univariate Cox regression analysis for cardiovascular
congestion
Variables
Hazard ratio
(95% CI) P-value
Age 1.01 (0.99–1.03) 0.21
Male gender 1.17 (0.76–1.79) 0.48
Positive smoking history 1.63 (1.06–2.51) 0.026
Dialysis duration 0.995 (0.987–1.003) 0.19
Body mass index 1.04 (0.97–1.11) 0.25
Clinical atherosclerotic vascular disease 2.37 (1.50–3.74) o0.001
Diabetes 2.14 (1.38–3.30) 0.001
Serum albumin 0.93 (0.89–0.97) 0.002
C-reactive protein 1.00 (0.99–1.02) 0.94
Hemoglobin 0.74 (0.64–0.86) o0.001
Parathyroid hormone 1.00 (1.00–1.01) 0.95
Calcium *phosphorus product 1.04 (0.90–1.22) 0.59
Systolic blood pressure 1.03 (1.02–1.04) o0.001
Diastolic blood pressure 1.01 (0.99–1.02) 0.94
High peritoneal transport 1.62 (0.96–2.72) 0.07
Residual glomerular filtration rate 0.89 (0.77–1.02) 0.09
Peritoneal dialysis urea clearance 0.81 (0.45–1.45) 0.47
Left ventricular mass index 1.012 (1.007–1.017) o0.001
Left ventricular ejection fraction 0.95 (0.93–0.97) o0.001
Troponin T 6.02 (3.10–11.68) o0.001
CI, confidence interval.
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peritoneal dialysis patients. The combination of troponin
T with LVMi and EF identifies peritoneal dialysis patients
with the greatest risk of cardiovascular congestion. Compared
to patients with troponin Tpmedian and preserved left
ventricular systolic function, those with troponin T4median
but preserved left ventricular systolic function showed a
nearly two-fold increase adjusted risk of cardiovascular
congestion while those with troponin Tpmedian, but systolic
dysfunction were at no greater risk of cardiovascular
congestion. This suggests troponin T elevation has greater
prognostic importance than depressed left ventricular systolic
function in determining peritoneal dialysis patients at
increased risk of cardiovascular congestion.
In this study, the diagnosis of cardiovascular congestion
was made by the attending physician, based on clinical and
radiological evidence of pulmonary congestion without
implications on the etiologic factor for the episode of
cardiovascular congestion. A previous study by our group
Table 4 | Multivariable Cox regression analysis of factors predicting cardiovascular congestion
Base modela Model 1 Model 2 Model 3
P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI)
Hemoglobin (1 g/dl m) 0.016 0.84 (0.72, 0.97) 0.091 0.88 (0.76, 1.02) 0.064 0.87 (0.76, 1.01) 0.081 0.88 (0.76, 1.02)
Serum albumin (1 g/l m) 0.010 0.94 (0.89, 0.99) 0.015 0.94 (0.90, 0.99) 0.014 0.94 (0.89, 0.99) 0.062 0.95 (0.90, 1.00)
Diabetes mellitus 0.035 1.64 (1.03, 2.60) 0.036 1.64 (1.03, 2.61) 0.115 1.46 (0.91, 2.35) 0.167 1.40 (0.87, 2.26)
Systolic blood pressure (1 mm Hg m) o0.001 1.03 (1.01, 1.04) o0.001 1.03 (1.01, 1.04) o0.001 1.03 (1.01, 1.04) o0.001 1.03 (1.02, 1.04)
Atherosclerotic vascular disease 0.003 2.08 (1.29, 3.36) 0.007 1.95 (1.20, 3.16) 0.026 1.75 (1.07, 2.87) 0.019 1.80 (1.10, 2.93)
LVMi (1 g/m2.7 m) — — 0.016 1.007 (1.001, 1.012) 0.050 1.006 (1.000, 1.011) 0.143 1.004 (0.999, 1.010)
Ejection fraction (1% m) — — — — 0.014 0.97 (0.94, 0.99) 0.049 0.97 (0.95, 1.00)
Troponin T (1 mg/l m) — — — — — — 0.019 2.98 (1.19, 7.42)
Overall w2 55.633 — 60.904 — 66.254 — 75.157 —
LVMi, left ventricular mass index; HR, hazard ratio; CI, confidence intervals.
aCovariates considered in the initial model were age, diabetes mellitus, positive smoking history, background AVD, dialysis duration, systolic blood pressure, hemoglobin,
serum albumin, residual glomerular filtration rate, and high peritoneal transport by peritoneal equilibration test.
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Figure 1 | The Kaplan–Meier estimates of cardiovascular
congestion event-free probability in patients stratified by
quartiles of troponin T (TnT). Log-rank test showed significant
difference in cardiovascular congestion-free probability between
Quartile 1 and 3 (P¼ 0.0001), Quartile 1 and 4 (Po0.0001),
Quartile 2 and 4 (P¼ 0.0025) but not between Quartile 1 and 2
(P¼ 0.12), Quartile 2 and 3 (P¼ 0.10), and Quartile 3 and 4
(P¼ 0.22).
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Figure 2 | Episodes of cardiovascular congestion during follow-
up. (a) The Kaplan–Meier estimates of cardiovascular congestion
event-free probability in patients stratified into four groups
(groups I–IV) based on the combination of troponin T (TnT) and
LVMi. Group I (n¼ 79): TnTrmedian (0.06 mg/l), LVMi omedian
(96.23 g/m2.7); group II (n¼ 39): TnT4median, LVMi omedian;
group III (n¼ 32): TnTrmedian, LVMiZmedian; group IV (n¼ 72):
TnT4median, LVMiZmedian. Log-rank test showed significant
difference in cardiovascular congestion event-free probability
between group I and II (P¼ 0.02), group I and III (P¼ 0.001),
group I and IV (Po0.0001), group II and IV (P¼ 0.008), and group III
and IV (P¼ 0.05) but not between group II and III (P¼ 0.25).
(b) Prevalence and frequency of recurrence of cardiovascular
congestion in patients stratified into four groups on the basis of
LVMi and troponin T (TnT).
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clearly showed that peritoneal dialysis patients with previous
history of cardiovascular congestion, irrespective of the
etiology, had greater left ventricular hypertrophy, dilatation
and dysfunction.40 Putting this together with our current
finding that troponin T elevation was positively associated
with left ventricular mass and negatively associated with left
ventricular systolic function and was predictive of subsequent
risk of cardiovascular congestion, our results may be
interpreted in two ways. Firstly, an episode of cardiovascular
congestion even though seemingly reversible with hypertonic
exchanges may increase left ventricular hypertrophy, dysfunc-
tion, and myocardial damage. Secondly, patients with
previous history of cardiovascular congestion may actually
remain in a subclinical volume overload state persistently,
thus resulting in greater left ventricular hypertrophy and
dysfunction. Whichever is the case, troponin T elevation
reflects the degree of left ventricular dysfunction more
precisely than EF, thus explains its prognostic importance
for cardiovascular congestion. Our results are well in keeping
with recent study showing that severe coronary artery
disease alone could not explain elevated troponin T in
dialysis patients.41 Troponin T elevation reflects myocardial
dysfunction and probably subclinical cellular damage as
evidenced by left ventricular dilatation, impaired left
ventricular systolic function, and raised left ventricular filling
pressure.41
Study limitations
First, cardiovascular congestion was defined as such to
include only episodes that require hospitalization. Patients
presenting with milder symptoms of cardiovascular conges-
tion such as ankle edema that do not require hospitalization
were considered as event-free. This may result in an
underestimation of the true incidence of cardiovascular
congestion in our peritoneal dialysis patients. Second,
echocardiography was not performed at the time of
cardiovascular congestion. Thus, we were not able to
determine whether cardiovascular congestion is due to
cardiac dysfunction or fluid noncompliance. However, even
with echocardiography this distinction is not easy. Third, a
single troponin T was measured at study baseline and did
not take into account of changes over time. Fourth, the study
was performed in end-stage renal disease patients on
maintenance peritoneal dialysis. Whether our results can
also be generalized to hemodialysis patients and patients
Table 5 | Stepwise multivariable Cox regression analysis of predictors of cardiovascular congestion with patients stratified in
four groups according to troponin T and LVMi
P Hazard ratios 95% CI
Hemoglobin (1 g/dl m) 0.061 0.87 0.76, 1.01
Serum albumin (1 g/l m) 0.019 0.94 0.89, 0.99
Systolic blood pressure (mm Hg m) o0.001 1.03 1.01, 1.04
Known clinical atherosclerotic vascular disease 0.019 1.80 1.10, 2.95
Left ventricular ejection fraction (% m) 0.032 0.968 0.943, 0.997
Troponin T and LVMi stratified in four groups (with troponin Trmedian, LVMi omedian as reference group)
Troponin T4median, LVMi omedian vs troponin Trmedian, LVMi omedian 0.097 1.91 0.89, 4.10
Troponin Trmedian, LVMiZmedian vs troponin Trmedian, LVMi o median 0.148 1.72 0.83, 3.58
Troponin T4median, LVMiZmedian vs troponin Trmedian, LVMi o median 0.003 2.68 1.39, 5.19
CI, confidence intervals; LVMi, left ventricular mass index.
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Figure 3 | Episodes of cardiovascular congestion during follow-
up. (a) The Kaplan–Meier estimates of cardiovascular congestion
event-free probability in patients stratified into four groups (groups
I–IV) on the basis of troponin T and left ventricular ejection fraction
(LVEF). Group I (n¼ 94): TnTrmedian (0.06 mg/l), LVEF450%; group II
(n¼ 24): TnT4median, LVEF450%; group III (n¼ 55): TnTrmedian,
LVEFr50%; group IV (n¼ 49): TnT4median, LVEFr50%. Log-rank
test showed significant difference in cardiovascular congestion-free
probability between groups I and III (P¼ 0.002), groups I and IV
(Po0.0001), groups II and IV (P¼ 0.005), and groups III and IV
(P¼ 0.005) but not between groups I and II (P¼ 0.38) and groups II
and III (P¼ 0.25). (b) Prevalence and frequency of recurrence of
cardiovascular congestion in patients stratified into four groups on
the basis of left ventricular ejection fraction (LVEF) and troponin T.
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with other stages of chronic kidney disease need further
evaluation.
Implications
Our study has several important implications. First, given
that troponin T remains a powerful predictor of cardiovas-
cular congestion in chronic peritoneal dialysis patients
independent of left ventricular mass and systolic function,
this strengthens the utility of troponin T testing as a regular
cardiovascular risk assessment and monitoring tool in
peritoneal dialysis patients without acute myocardial ische-
mia. Second, the finding that troponin T testing has
additional prognostic value to conventional echocardio-
graphic parameters suggests troponin T should be measured
in conjunction with echocardiography for cardiovascular risk
stratification in order to identify peritoneal dialysis patients
at risk of cardiovascular congestion. Third, in view that
troponin T elevation in peritoneal dialysis patients may
reflect subclinical myocardial injury rather than acute
coronary syndrome, the correct troponin T cutoff for
diagnosing acute coronary syndrome in peritoneal dialysis
patients needs to be re-defined.
Conclusions
Troponin T is a powerful, independent predictor for
cardiovascular congestion and adds significant value to
echocardiography in identifying peritoneal dialysis patients
at risk of cardiovascular congestion.
MATERIALS AND METHODS
Study design and patients
The study protocol was approved by the Clinical Research Ethics
Committee of the Chinese University of Hong Kong. All patients
provided informed consent prior to study entry. The study
population consisted of 222 consecutive end-stage renal disease
patients receiving continuous ambulatory peritoneal dialysis treat-
ment at the outpatient dialysis unit of the Prince of Wales Hospital,
Hong Kong and they represented 82% of the total peritoneal dialysis
population (n¼ 270) at the unit. Patients were considered eligible
for study inclusion if they have received peritoneal dialysis treatment
for 3 months or more. The remaining 18% of patients were excluded
based on the exclusion criteria which included patients with acute
coronary syndrome, acute heart failure, underlying malignancy,
chronic liver disease, systemic lupus erythematosus, chronic
rheumatic heart disease, congenital heart disease, patients who
refused to give consent, patients on automated peritoneal dialysis, or
patients with incomplete data. All patients were dialyzed using
conventional lactate buffered glucose-based peritoneal dialysis
solutions.
This study is based on a prospective cohort who was followed up
longitudinally for 3 years from the day of study entry. At study entry,
baseline echocardiography was performed together with measure-
ment of residual renal function and indices of dialysis adequacy. At
the same time, blood samples were collected for measurement of
troponin T and other biochemical parameters. Demographic and
clinical data of study patients were also recorded at study entry.
Known clinical atherosclerotic vascular disease was defined as the
presence of ischemic heart disease (indicated by history of angina,
previous myocardial infarction with or without history of coronary
artery bypass surgery or stenting), cerebrovascular disease (indicated
by history of cerebrovascular event or transient ischemic attack),
and peripheral vascular disease (indicated by the presence of
intermittent claudication or resting leg pain, together with clinical
signs of peripheral vascular disease with or without history of
amputation or revascularization). The systolic and diastolic blood
pressure measured on every follow-up visit at 8-week intervals for
the 12 months preceding study entry were averaged to give the final
systolic and diastolic blood pressure in each patient.
Echocardiography
Two-dimensional echocardiography was performed using a GE-
VingMed System 5 echocardiographic machine (GE-VingMed
Sound AB, Horten, Norway) with a 3.3 mHz multiphase array
probe in subjects lying in the left decubitus position by a single
experienced cardiologist blinded to all clinical details of patients. All
echocardiographic data were recorded according to the guidelines of
the American Society of Echocardiography.42 Mitral inflow velocities
and diastolic filling were assessed by Doppler echocardiography as
previously described.43 Left ventricular mass was indexed by height
rather than body surface area in order to minimize potential
distortion by extracellular volume expansion. Left ventricular mass
indexed by height has been shown to provide more powerful
prediction for mortality and cardiovascular events.44 Left ventricular
hypertrophy was defined as LVMi 447 g/m2.7 in women and 450 g/
m2.7 in men. The EF was obtained using a modified biplane
Simpson’s method from apical two and four chamber views.45
Biochemical measurements
Ethylene diaminetetraacetic acid and heparin blood samples were
collected at baseline for measurement of troponin T, C-reactive
Table 6 | Stepwise multivariable Cox regression analysis of predictors of cardiovascular congestion with patients stratified in
four groups according to troponin T and left ventricular ejection fraction
P-value Hazard ratios 95% CI
Hemoglobin (1 g/dl m) 0.048 0.65 0.75, 1.00
Serum albumin (1 g/l m) 0.034 0.95 0.90, 1.00
Systolic blood pressure (1 mm Hg m) o0.001 1.03 1.01, 1.04
Known clinical atherosclerotic vascular disease 0.005 1.99 1.23, 3.21
Troponin T and LVEF stratified in four groups (with troponin Trmedian, LVEF450% as reference group)
troponin T4median, LVEF450% vs troponin Trmedian, LVEF450% 0.034 1.88 1.05, 3.38
troponin Trmedian, LVEFr50% vs troponin Trmedian, LVEF450% 0.398 1.42 0.63, 3.19
troponin T4median, LVEFr50% vs troponin Trmedian, LVEF450% o0.001 3.10 1.71, 5.63
CI, confidence intervals; LVEF, left ventricular ejection fraction.
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protein, albumin, and hemoglobin. Troponin T in ethylene
diaminetetraacetic acid plasma was measured by electrochemilumi-
nescence immunoassay (Roche Modular analyzer, Roche Diagnostic
GmbH, Mannheim, Germany) with a detection limit of 0.01 mg/l
and an inter-assay coefficient of variation of 4.8% at 0.18 mg/l.
C-reactive protein and albumin in heparin plasma were measured,
respectively, using the Tina-quant C-reactive protein latex high
sensitive assay (detection limit of 0.01 mg/l and coefficient of
variation of 1.6% at 2.0 mg/l) and the bromocresol purple method
(coefficient of variation of 2.8% at 45 g/l) on the Roche analyzer.
Indices of dialysis adequacy
Residual glomerular filtration rate was measured as the average of
24-h urine urea and creatinine clearance.46 Adequacy of dialysis was
estimated by measuring total weekly urea clearance and creatinine
clearance using standard methods.47 Creatinine concentration in
dialysate was corrected for interference by glucose according to the
reference formula determined in our laboratory.48 Contribution of
peritoneal dialysis and renal component to the total urea clearance
was estimated separately. Total body water was derived using the
Watson formula.49 A standard peritoneal equilibration test was
performed to determine the peritoneal transport characteristics.
In patients who developed acute coronary syndrome, acute
cardiovascular congestion, peritonitis, exit site infections or any
other infective complications, all the above assessments were
deferred for at least 1 month after complete resolution of the
complication.
Outcome measure
All patients were prospectively followed up for 3 years from the day
of the baseline assessments or until death or permanent transfer to
alternative mode of renal replacement therapy. No patient was lost
to follow-up. The outcome measure was the first episode of
cardiovascular congestion. The outcome was defined ‘a priori’ and
the cohort was purposely assembled to examine this complication.
Cardiovascular congestion was defined as such to include only
episodes that were clearly documented to require hospitalization.
This was assessed by using the computerized Clinical Management
System of the Hong Kong Hospital Authority and the Renal Registry
Database, developed and maintained by the Hong Kong Central
Renal Committee and they keep detailed record of all hospitalization
episodes. Essentially, the diagnosis was established by the attending
physician based on the presence of the following three clinical
criteria without preceding knowledge of the troponin T result: first,
presence of symptoms and signs of heart failure including dyspnoea,
raised jugular venous pressure and basal crepitations; second,
radiographic evidence of pulmonary venous congestion or inter-
stitial edema;1 third, resolution of symptoms, signs and radiographic
changes with hypertonic peritoneal dialysis exchanges. In patients
who presented to the outpatient clinic with milder symptoms of
cardiovascular congestion including ankle edema or facial puffiness
and not requiring hospitalization, the episode would not be counted
as cardiovascular congestion.
Statistical analysis
Continuous data are represented as mean7s.d. or median
(interquartile range) depending on the distribution. Comparisons
between patients with and without cardiovascular congestion were
performed by the t-test, Mann–Whitney U-test or w2 test, as
appropriate. Correlations were tested using Spearman rank correla-
tion analysis. Patients were stratified into quartiles according to their
baseline troponin T concentrations. Survival analysis was based on
the time to develop the first event of cardiovascular congestion.
Survival curves of the four quartiles were generated by the
Kaplan–Meier estimates and differences in survival among the four
quartiles were compared by the Mantel log-rank test. Patients were
censored at the time of transfer to alternative renal replacement
therapy or at their death.
To evaluate the effect of baseline troponin T in predicting
cardiovascular congestion, relative risks and 95% confidence
intervals (CI) were calculated as hazard ratios derived from the
Cox proportional-hazards regression model. Factors with Po0.25 in
the univariate analysis (excluding terms for LVMi, left ventricular
EF, and troponin T) were first considered in the multivariable Cox
regression analysis. A backward elimination procedure (with
Po0.05) was applied to choose the base model. Subsequent
multivariable Cox regression analyses were performed by sequen-
tially adding LVMi, EF, and troponin T as continuous variables to
the base model. In order to further evaluate how troponin T
influenced the prognostic value of LVMi for cardiovascular
congestion, patients were stratified into four groups on the basis
of troponin T4median or pmedian and LVMiXmedian and
omedian. Survival curves were generated by means of the
Kaplan–Meier estimates and differences in survival among the four
groups were compared by the Mantel log-rank test. Multivariable
Cox regression models were additionally performed, considering the
same covariates in the basic model and including terms for LVMi,
EF, and troponin T. However, in these models, troponin T and LVMi
were entered as a combined nominal variable, stratified into four
groups as described above (with troponin Tpmedian and
LVMiomedian as the reference group). A backward elimination
procedure (with Po0.05) was applied to choose the final model.
Similar analyses were carried out with patients stratified into four
groups on the basis of troponin T4median or pmedian and
EF450% and p50% (with troponin Tpmedian and EF450% as
the reference group). All P-values were two-tailed. A P-value of less
than 0.05 was considered to be statistically significant. Statistical
analysis was performed using SPSS version 14.0 (SPSS, Inc.,
Chicago, Illinois, USA).
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